Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Intelligent Bio Solutions Inc. successfully completed its initial clinical Cut-off Study for its Intelligent Fingerprinting Drug Screening System detecting opiate codeine, progressing its FDA 510(k) submission process. The company has initiated the second phase clinical studies, including Method Comparison, Usability, and Interference Testing, targ…